Stem Cell Training and Bioheart, Inc. have announced plans to launch a post-graduate studies program in stem cell and regenerative medicine, to be conducted in Miami in 2015.
Stem Cell Training, Inc., a division of Global Stem Cells Group, Inc., has announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2015.
The program will include five days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices.
Global Stem Cells Group Advisory Board member Dr. David B. Harrell, PhD will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.
Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and FDA registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting
The graduate course is to be held four times in Miami in 2015.
Course details, objectives and instruction include:
Plating Stem Cells
Harvesting and Freezing stem cells (perform counts and flow)
Gowning to enter cleanroom
Calibration and PM
Didactic Lectures will include:
Stem Cell Biology
Quality control: endotoxin, sterility, mycoplasma
Gowning to enter cleanroom
For additional information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
About David B. Harrell, PhD, Brt, OF, FAABRM, FRIPH:
David B. Harrell received his PhD in Molecular Biology, focusing on inter- and intra-cellular communications. Harrell pursued post-doctoral studies at Harvard, Yale, and the University of Rochester and holds national and international awards for his groundbreaking research in signal transduction and cellular communication. Harrell is the owner and chief consultant of Harrell BioScience Consulting, LLC.
Named to Who’s Who in Molecular Biology as well as Public Health and Epidemiology, Harrell is an active reviewer and sits on the editorial boards of several clinical and scientific journals, as well as government agencies. Harrell has several publications in the areas of tissue regeneration, stem cells, neuroscience and epidemiology, and now focuses heavily on translational research. He is a member of the Board of Directors of the American Academy and Board of Regenerative Medicine.